Literature DB >> 3469331

Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors.

T Hori, K Muraoka, Y Saito, K Sasahara, H Inagaki, Y Inoue, S Adachi, Y Anno.   

Abstract

The water-soluble nitrosourea compound ACNU is also lipid-soluble at normal physiological pH levels. It lacks toxic effects on vision that nitrosoureas occasionally produce following intra-arterial administration. In 28 cases of both primary and secondary malignant brain tumors, ACNU was administered at surgery or angiography by three different modes: intravenous injection in Group I (10 cases), intra-arterial injection via the carotid artery in Group II (11 cases), and intra-arterial injection via the carotid artery after opening the blood-brain barrier (BBB) by means of mannitol in Group III (seven cases). Tumor tissue and blood samples were taken serially at various time intervals after ACNU injection, and ACNU was measured by high-performance liquid chromatography. The time-concentration curve for ACNU was calculated in each case by the two- and one-compartment open models for determination of ACNU levels in blood and tissue, respectively. Pharmacokinetic parameters including biological half-life, blood and tissue levels (0-t minutes and 0-infinity minutes), total plasma clearance, and distribution volume of the beta phase were compared. Statistical analysis of tissue ACNU levels at 0-t minutes revealed higher concentrations in Group III patients than in Groups II and I: levels in Group II were significantly higher than in Group I. Mean biological half-life was 30.3, 23.0, and 38.5 minutes in Groups I, II, and III, respectively. Levels of ACNU were significantly increased in tumor tissue as well as in peritumoral tissue in one Group III patient with multiple metastatic anaplastic adenocarcinoma. In this series, treatment of malignant brain tumor by intra-arterial administration of ACNU produced significantly higher tissue levels of ACNU than did the systemic intravenous route.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3469331     DOI: 10.3171/jns.1987.66.3.0372

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  Intra-arterial chemotherapy for malignant gliomas: a critical analysis.

Authors:  J-K Burkhardt; H A Riina; B J Shin; J A Moliterno; C P Hofstetter; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?

Authors:  J C Tonn; K Roosen; W Schachenmayr
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

3.  Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.

Authors:  J C Tonn; R Schönmayr; H P Kraemer
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

4.  Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up.

Authors:  Y Mitsuhashi; Y Sugiyama; S Ozawa; T Nitanai; K Sasahara; K Nakamura; M Tanaka; T Nishimura; M Inaba; T Kobayashi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines.

Authors:  Katsuhiko Kono; Jun A Takahashi; Tetsuya Ueba; Hisae Mori; Nobuo Hashimoto; Manabu Fukumoto
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Intra-arterial chemotherapy for brain stem glioma: report of four cases.

Authors:  T Fujiwara; T Ogawa; K Irie; T Tsuchida; S Nagao; M Ohkawa
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

Review 7.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Authors:  J C Buckner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

8.  In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours.

Authors:  U Bogdahn; D Drenkard; M Lutz; R Apfel; C Behl
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Modulation of BUdR labeling index in rat brain tumors following intracarotid ACNU administration.

Authors:  K Mineura; K Watanabe; I Izumi; M Kowada
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

Review 10.  Novel therapeutic delivery approaches in development for pediatric gliomas.

Authors:  Katherine E Warren
Journal:  CNS Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.